498 related articles for article (PubMed ID: 24871131)
1. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
Cha E; Klinger M; Hou Y; Cummings C; Ribas A; Faham M; Fong L
Sci Transl Med; 2014 May; 6(238):238ra70. PubMed ID: 24871131
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
Rudqvist NP; Pilones KA; Lhuillier C; Wennerberg E; Sidhom JW; Emerson RO; Robins HS; Schneck J; Formenti SC; Demaria S
Cancer Immunol Res; 2018 Feb; 6(2):139-150. PubMed ID: 29180535
[TBL] [Abstract][Full Text] [Related]
3. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
Oh DY; Cham J; Zhang L; Fong G; Kwek SS; Klinger M; Faham M; Fong L
Cancer Res; 2017 Mar; 77(6):1322-1330. PubMed ID: 28031229
[TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
Cham J; Zhang L; Kwek S; Paciorek A; He T; Fong G; Oh DY; Fong L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376721
[TBL] [Abstract][Full Text] [Related]
5. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
Agarwalla P; Barnard Z; Fecci P; Dranoff G; Curry WT
J Immunother; 2012 Jun; 35(5):385-9. PubMed ID: 22576343
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
Front Immunol; 2018; 9():14. PubMed ID: 29403496
[TBL] [Abstract][Full Text] [Related]
7. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
8. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
9. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
[TBL] [Abstract][Full Text] [Related]
10. Differences in the requirement of antigen-presenting cells for long-term growth among cytomegalovirus-specific Th clonotypes.
Santamaria P; Lewis C; Barbosa JJ
Eur J Immunol; 1993 Nov; 23(11):2972-9. PubMed ID: 8223874
[TBL] [Abstract][Full Text] [Related]
11. CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
Robert L; Tsoi J; Wang X; Emerson R; Homet B; Chodon T; Mok S; Huang RR; Cochran AJ; Comin-Anduix B; Koya RC; Graeber TG; Robins H; Ribas A
Clin Cancer Res; 2014 May; 20(9):2424-32. PubMed ID: 24583799
[TBL] [Abstract][Full Text] [Related]
12. 3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data.
Zhang L; Cham J; Paciorek A; Trager J; Sheikh N; Fong L
BMC Bioinformatics; 2017 Feb; 18(1):129. PubMed ID: 28241742
[TBL] [Abstract][Full Text] [Related]
13. T Cell Receptor Diversity and Lineage Relationship between Virus-Specific CD8 T Cell Subsets during Chronic Lymphocytic Choriomeningitis Virus Infection.
Chang YM; Wieland A; Li ZR; Im SJ; McGuire DJ; Kissick HT; Antia R; Ahmed R
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759317
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
Buchbinder E; Hodi FS
J Clin Invest; 2015 Sep; 125(9):3377-83. PubMed ID: 26325034
[TBL] [Abstract][Full Text] [Related]
15. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer.
Ali LR; Lenehan PJ; Cardot-Ruffino V; Dias Costa A; Katz MHG; Bauer TW; Nowak JA; Wolpin BM; Abrams TA; Patel A; Clancy TE; Wang J; Mancias JD; Reilley MJ; Stucky CH; Bekaii-Saab TS; Elias R; Merchant N; Slingluff CL; Rahma OE; Dougan SK
Clin Cancer Res; 2024 Feb; 30(3):542-553. PubMed ID: 37733830
[TBL] [Abstract][Full Text] [Related]
16. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Yuan J; Gnjatic S; Li H; Powel S; Gallardo HF; Ritter E; Ku GY; Jungbluth AA; Segal NH; Rasalan TS; Manukian G; Xu Y; Roman RA; Terzulli SL; Heywood M; Pogoriler E; Ritter G; Old LJ; Allison JP; Wolchok JD
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20410-5. PubMed ID: 19074257
[TBL] [Abstract][Full Text] [Related]
17. Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8(+) T cell receptor alpha repertoire following allogeneic transplantation.
Link CS; Eugster A; Heidenreich F; Rücker-Braun E; Schmiedgen M; Oelschlägel U; Kühn D; Dietz S; Fuchs Y; Dahl A; Domingues AM; Klesse C; Schmitz M; Ehninger G; Bornhäuser M; Schetelig J; Bonifacio E
Clin Exp Immunol; 2016 Jun; 184(3):389-402. PubMed ID: 26800118
[TBL] [Abstract][Full Text] [Related]
18. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model.
Son CH; Bae JH; Shin DY; Lee HR; Choi YJ; Jo WS; Ho Jung M; Kang CD; Yang K; Park YS
J Immunother; 2014 Jan; 37(1):1-7. PubMed ID: 24316550
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Grosso JF; Jure-Kunkel MN
Cancer Immun; 2013; 13():5. PubMed ID: 23390376
[TBL] [Abstract][Full Text] [Related]
20. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Hannani D; Vétizou M; Enot D; Rusakiewicz S; Chaput N; Klatzmann D; Desbois M; Jacquelot N; Vimond N; Chouaib S; Mateus C; Allison JP; Ribas A; Wolchok JD; Yuan J; Wong P; Postow M; Mackiewicz A; Mackiewicz J; Schadendorff D; Jaeger D; Zörnig I; Hassel J; Korman AJ; Bahjat K; Maio M; Calabro L; Teng MW; Smyth MJ; Eggermont A; Robert C; Kroemer G; Zitvogel L
Cell Res; 2015 Feb; 25(2):208-24. PubMed ID: 25582080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
